Asthma Therapeutics Market in Major Developed Economies to reach $21.7 billion by 2020.
Summary: The report includes complete market forecast upto 2020 for the major developed economies. It also discusses Asthma Therapeutics in great detail with all the necessary pipeline analysis.
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%.
Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Asthma Therapeutics In Major Developed Markets To 2020 - Personalized Treatment For Severe Asthma To Drive Market Growth Despite Patent Expirations at- http://www.marketreportsworld.com/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations-10070377
This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such...